3095
ALN-5288, An Investigational RNA Interference Therapeutic Targeting MAPT In Phase 1 Development For Alzheimer’s Disease
Kevin Sloan, Matthew Whittaker, Jeffrey Kurz, Shelley Patrick, Jon Farley, Rosalind Chuang, Julia Shirvan, Joe Dybowski, Kirk Brown
Alnylam Pharmaceuticals, Cambridge, MA, USA
Poster Presenter: Kevin Sloan
